Eli Lilly (NYSE:LLY) has announced that it would commercialize its Tempo personalized diabetes management platform in the U.S. before the end of 2022. The company anticipates full nationwide availability of the platform in 2023. Designed for adults with type 1 and 2 diabetes, the platform includes the Tempo Smart Button, a compatible app, and the…